SCHEMBL2267306

SCHEMBL2267306

O[C@H]1CCN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KCNA3 P22001 1/20 0.51
OPRL1 P41146 5/20 0.50
OPRM1 P35372 5/20 0.50
OPRK1 P41145 3/20 0.50
ALDH1A1 P00352 1/20 0.49
DPP4 P27487 1/20 0.48
SLC6A9 P48067 1/20 0.48
KMT2A Q03164 2/20 0.47
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
ADRA2A P08913 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CYP2D6 P10635 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
DRD1 P21728 1/20 0.47
ADRA1D P25100 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267354 1.00 L3MBTL3 (0.53) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL5745425 0.89 KDM4E (0.55) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL5745466 0.89 SLC6A9 (0.47) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL5745201 0.89 L3MBTL3 (0.61) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
Hydrochloric Acid SCHEMBL10797918 0.87 L3MBTL3 (0.59) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL48800 0.84 OPRM1 (0.48) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL5746042 0.83 OPRL1 (0.51) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
Hydrochloric Acid SCHEMBL741583 0.82 OPRM1 (0.47) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL19281773 0.82 OPRM1 (0.47) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1
SCHEMBL5240530 0.82 KCNA3 (0.49) L3MBTL3L3MBTL1KCNA3OPRL1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1693364-B1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI SANKYO CO LTD (JP) 2015-05-20 EP disclosed
US-7994344-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-7569599-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-05-24 US disclosed
EP-1693364-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates RAP1A, RHOA, MGMT L3MBTL3 2636/4885L3MBTL1 3585/4885KCNA3 602/4885
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES RAP1A, RHOA, MGMT L3MBTL3 2636/4885L3MBTL1 3585/4885KCNA3 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.